100 Years and Counting: Prospects for Defeating Alzheimer's Disease

This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pipeline. Among the investigative AD therapies in clinical trials are several strategies to block pathogenic amyloid-β peptides and to rescue vulnerable neurons from degeneration. Complementary but less mature strategies aim to prevent the copathogenic effects of apolipoprotein E and the microtubule-associated protein tau. New insights into selective neuronal vulnerability and the link between aging and AD may provide additional entry points for therapeutic interventions. The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency.

[1]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[2]  N. Hirokawa,et al.  Altered microtubule organization in small-calibre axons of mice lacking tau protein , 1994, Nature.

[3]  G. Dawson,et al.  β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity , 1995, Cell.

[4]  R. Weindruch,et al.  Oxidative Stress, Caloric Restriction, and Aging , 1996, Science.

[5]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[6]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[7]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[8]  D. Selkoe,et al.  Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease , 2000, Annals of neurology.

[9]  B. Wolozin.  A fluid connection: Cholesterol and Aβ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[11]  C. Haass,et al.  A γ‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish , 2002, EMBO reports.

[12]  R. Mayeux,et al.  Caloric intake and the risk of Alzheimer disease. , 2002, Archives of neurology.

[13]  T. Saido,et al.  Region‐specific reduction of Aβ‐degrading endopeptidase, neprilysin, in mouse hippocampus upon aging , 2002, Journal of neuroscience research.

[14]  M. Staufenbiel,et al.  Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy , 2002, Science.

[15]  M. Tuszynski,et al.  Growth-factor gene therapy for neurodegenerative disorders , 2002, The Lancet Neurology.

[16]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[17]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[18]  J. Regula,et al.  Reconstitution of γ-secretase activity , 2003, Nature Cell Biology.

[19]  Paul Greengard,et al.  Gleevec inhibits β-amyloid production but not Notch cleavage , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[21]  F. Gage,et al.  Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.

[22]  Thomas Wisniewski,et al.  A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice , 2004 .

[23]  M. Citron,et al.  Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[24]  B. Hyman,et al.  Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation , 2004, Nature Medicine.

[25]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.

[26]  Anne Whitehead,et al.  Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trials , 2004, International journal of geriatric psychiatry.

[27]  D. Alkon,et al.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Citron.  Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.

[29]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[30]  J. Wesson Ashford,et al.  ApoE genotype accounts for the vast majority of AD risk and AD pathology , 2004, Neurobiology of Aging.

[31]  David Ames,et al.  Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[32]  D. Peterson,et al.  Neural stem cells as therapeutic agents for age‐related brain repair , 2004, Aging cell.

[33]  F. Liu,et al.  Post-translational modifications of tau protein in Alzheimer’s disease , 2005, Journal of Neural Transmission.

[34]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[35]  M. Farlow.  Utilizing combination therapy in the treatment of Alzheimer’s disease , 2004, Expert review of neurotherapeutics.

[36]  B. Winblad,et al.  An active and socially integrated lifestyle in late life might protect against dementia , 2004, The Lancet Neurology.

[37]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[38]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[40]  Steven G Potkin,et al.  A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.

[41]  G. Johnson,et al.  Tau phosphorylation: physiological and pathological consequences. , 2005, Biochimica et biophysica acta.

[42]  Pritam Das,et al.  Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production , 2005, Nature Medicine.

[43]  D. Praticò,et al.  Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti‐inflammatory drugs , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[45]  P. Doering,et al.  Vitamin C and Vitamin E for Alzheimer's Disease , 2005, The Annals of pharmacotherapy.

[46]  M. Higuchi,et al.  Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation , 2005, Nature Medicine.

[47]  Ilana S. Hairston,et al.  Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice , 2005, Cell.

[48]  H. Weiner,et al.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. , 2005, The Journal of clinical investigation.

[49]  C. Cotman,et al.  The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology , 2005, Journal of neuropathology and experimental neurology.

[50]  Inder M Verma,et al.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[52]  D. Selkoe,et al.  γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site* , 2005, Journal of Biological Chemistry.

[53]  A M Pittman,et al.  The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. , 2005, Human molecular genetics.

[54]  Robert A. Dean,et al.  Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.

[55]  F. LaFerla,et al.  M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.

[56]  L. Mucke,et al.  PKCε increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice , 2006 .

[57]  Xudong Huang,et al.  RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. , 2006, Current Alzheimer research.

[58]  K. Sleegers,et al.  Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[59]  D. Westaway,et al.  TMP21 is a presenilin complex component that modulates γ-secretase but not ɛ-secretase activity , 2006, Nature.

[60]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[61]  S. Deeks.  Antiretroviral treatment of HIV infected adults , 2006, BMJ : British Medical Journal.

[62]  M. Maggini,et al.  Cholinesterase Inhibitors: Drugs Looking for a Disease? , 2006, PLoS medicine.

[63]  G. Martino,et al.  The therapeutic potential of neural stem cells , 2006, Nature Reviews Neuroscience.

[64]  M. Ohno,et al.  Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1 , 2006, The European journal of neuroscience.

[65]  J. Grimm,et al.  Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice , 2006, The Journal of Neuroscience.

[66]  E. Mandelkow,et al.  Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy , 2006, Journal of Biological Chemistry.

[67]  J. Obeso,et al.  Timing of treatment initiation in Parkinson's disease: A need for reappraisal? , 2006, Annals of neurology.

[68]  L. Mucke,et al.  Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease , 2006, Neuron.

[69]  D. Bredesen,et al.  Correction for Galvan et al., Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Growdon,et al.  Current pharmacotherapy for Alzheimer's disease. , 2006, Annual review of medicine.

[72]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[73]  Immunology and immunotherapy of Alzheimer's disease , 2006, Nature Reviews Immunology.

[74]  P. Doraiswamy,et al.  Pharmacological strategies for the prevention of Alzheimer’s disease , 2006, Expert opinion on pharmacotherapy.

[75]  R. Bullock.  Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date , 2006, Alzheimer disease and associated disorders.

[76]  O. Lindvall,et al.  Stem cells for the treatment of neurological disorders , 2006, Nature.

[77]  M. Wolfe.  The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble , 2006 .

[78]  Xiongwei Zhu,et al.  Involvement of Oxidative Stress in Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[79]  C. Lemere,et al.  Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response , 2006, The Journal of Neuroscience.

[80]  Jun Wang,et al.  Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction* , 2006, Journal of Biological Chemistry.

[81]  K. Weisgraber,et al.  Apolipoprotein E structure: insights into function. , 2006, Trends in biochemical sciences.

[82]  L. Petrucelli,et al.  HSP induction mediates selective clearance of tau phosphorylated at proline‐directed Ser/Thr sites but not KXGS (MARK) sites , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.